Related Experiment Video

Updated: Oct 26, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations

Hélène Vanacker1, Philipp Harter2, Sana Intidhar Labidi-Galy3

  • 1Centre Léon Bérard, Lyon, France; University Claude Bernard Lyon 1, France.

Cancer Treatment Reviews
|July 31, 2021
PubMed

Insights

Poly-(ADP)-ribose polymerase inhibitors (PARPi) offer new hope for ovarian cancer patients. This review explores their use in recurrent and frontline settings, highlighting biomarker roles and future combination therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Poly-(ADP)-ribose polymerase inhibitors (PARPi) are oral anticancer drugs.
  • Initially developed for BRCA1/BRCA2-mutated cancers, PARPi exploit synthetic lethality.
  • PARPi have shown efficacy in high-grade serous or endometrioid ovarian cancers (HGOC).

Purpose of the Study:

  • To review the current applications of PARPi in ovarian cancer.
  • To discuss PARPi's role in recurrent and frontline maintenance therapy.
  • To explore biomarker identification, resistance mechanisms, and future combination strategies.

Main Methods:

  • Literature review of PARPi in ovarian cancer treatment.
  • Analysis of clinical trial data and research findings.
  • Synthesis of information on biomarkers, resistance, and novel combinations.

Main Results:

  • PARPi are beneficial as maintenance therapy in relapsed BRCA-mutated and non-mutated HGOC.
  • PARPi indications have expanded to frontline maintenance therapy.
  • Biomarker identification, resistance, and combination therapies are key areas of ongoing research.

Conclusions:

  • PARPi are established agents in recurrent and frontline ovarian cancer maintenance therapy.
  • Overcoming resistance and exploring combinations with targeted therapies are crucial for future progress.
  • Further research into biomarkers and novel drug combinations will enhance PARPi efficacy.
Keywords:
BRCAHRDNiraparibOlaparibOvarian cancerPARP inhibitorRucaparib, Veliparib

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.9K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K